Aldosterone excess and resistant hypertension: Investigation and treatment

Current Hypertension Reports

Volumn 16, Issue 7, 2014, Pages

  Stowasser, Michael ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Adrenal venous sampling; Aldosterone; Aldosterone renin ratio; Complications; Confirmation; Familial; Genetics; Prevalence; Primary aldosteronism; Quality of life; Screening; Subtype differentiation; Treatment

Indexed keywords

ALDOSTERONE; AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FINERENONE; SPIRONOLACTONE; RENIN;

ARTICLE; ASSAY; DIAGNOSTIC PROCEDURE; GENETICS; HUMAN; KNOWLEDGE; METHODOLOGY; MORBIDITY; PRIMARY HYPERALDOSTERONISM; QUALITY OF LIFE; RELIABILITY; RESISTANT HYPERTENSION; SCREENING; ANIMAL; DRUG RESISTANCE; HYPERTENSION; METABOLISM; REPRODUCIBILITY;

ALDOSTERONE; ANIMALS; DRUG RESISTANCE; HUMANS; HYPERTENSION; QUALITY OF LIFE; RENIN; REPRODUCIBILITY OF RESULTS;

EID: 84901728107     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0439-7     Document Type: Article

References (105)

1. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-6. (Pubitemid 35434912)
2. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699-705. (Pubitemid 32268029)
3. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-5.
4. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-8. (Pubitemid 44309817)
5. Rossi GP, Cesari M, Pessina AC. Left ventricular changes in primary aldosteronism. Am J Hypertens. 2003;16:96-8. (Pubitemid 36078602)
6. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001;28:783-91. (Pubitemid 32947172)
7. .• Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62:331-6. This large retrospective study reported that, compared with essential hypertensives (n=459) matched for age, sex and office systolic blood pressure, patients with PA (n=1290) were more likely to have left ventricular hypertrophy or coronary artery disease, and to have suffered a nonfatal myocardial infarct, heart failure or atrial fibrillation.
8. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-termcardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826-33.
9. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454-9. (Pubitemid 43236909)
10. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm Metab Res. 2010;42:435-9.
11. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20:855-61. (Pubitemid 47176347)
12. Williams TA, Monticone S, Urbanet R, Bertello C, Giraudo G, Vettor R, et al. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol. 2012;355:162-8.
13. Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98:2513-20.
14. Mark PB, Boyle S, Zimmerli LU, McQuarrie EP, Delles C, Freel EM. Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study. J Hum Hypertens. 2014;28:92-7.
15. Su MY, Wu VC, Yu HY, Lin YH, Kuo CC, Liu KL, et al. Contrast-enhanced MRI index of diffuse myocardial fibrosis is increased in primary aldosteronism. J Magn Reson Imaging. 2012;35:1349-55.
16. Lin YH, Lee HH, Liu KL, Lee JK, Shih SR, Chueh SC, et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery. 2011.
17. Lin YH, Lin LY, Chen A, Wu XM, Lee JK, Su TC, et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis. 2012;221:154-9.
18. Catena C, Colussi GL,Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res. 2012;44:188-93.
19. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009;51:371-80.
20. .• Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab. 2011;96:E878-83. This carefully performed case-control study found anxiety and stress to be more common among patients with PA(n=23) than those with essential hypertension (n=23).
21. Houlihan DJ. Episodic rage associated with primary aldosteronism resolved with adrenalectomy. Psychother Psychosom. 2011;80:306-7.
22. Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95:1360-4.
23. .• Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011;96:2904-11. Sthis study found quality of life scores among 21 patients with bilateral PA to be subnormal at baseline, and to have improved after 6 months of specific medical therapy, but more slowly and to a lesser degree than surgical treatment had previously been shown to improve quality of life scores in 22 patients with unilateral PA.
24. Gordon RD. Primary aldosteronism. J Endocrinol Invest. 1995;18:495-511.
25. Stowasser M, Gordon RD. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist. 2004;14:267-76. (Pubitemid 39232121)
26. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. Clin Biochem Rev. 2010;31:39-56.
27. Kerstens MN, Muller KAC, Volmer M, Koerts J, Sluiter WJ, Dullaart RP. Reference values for aldosterone-renin ratios in normotensive individuals and effect of changes in dietary sodium consumption. Clin Chem. 2011;57:1607-11.
28. Pizzolo F, Raffaelli R, Memmo A, Chiecchi L, Pavan C, Guarini P, et al. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Clin Endocrinol Metab. 2010;28:135-42.
29. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab. 2011;96:E340-6. FThis study reported (1) ARR levels to be higher in 19 normal premenopausal women than in 21 normal men, suggesting the need for new reference ranges that take gender into account; and (2) the occurrence of false-positive ARRs in two of the women during the luteal phase only when DRC (and not PRA) was used, suggesting that PRA is preferable to DRC in determination of ARR.
30. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011;96:1797-804.
31. Ahmed AH, Calvird M, Gordon RD, Taylor PJ,Ward G, Pimenta E, et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab. 2011;96:1039-45.
32. Pizzolo F, Zorzi F, Chiecchi L, Consoli L, Aprili I, Guarini P, et al. NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism. Endocrine. 2014;45:479-86.
33. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2003;17:591-605.
34. Westerdahl C, Bergenfelz A, Isaksson A, Valdemarsson S. Captopril suppression: Limitations for confirmation of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2011.
35. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin-Angiotensin- Aldosterone Syst. 2001;2:156-69. (Pubitemid 33685887)
36. Willenberg HS, Vonend O, Schott M, Gao X, Blondin D, Saleh A, et al. Comparison of the saline infusion test and the fludrocortisone suppression test for the diagnosis of primary aldosteronism. Horm Metab Res. 2012;44:527-32.
37. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995;207:565-71.
38. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-5.
39. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003;21:2149-57. (Pubitemid 38296877)
40. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227-35. (Pubitemid 39647538)
41. Weisbrod AB, Webb RC, Mathur A, Barak S, Abraham SB, Nilubol N, et al. Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism. Ann Surg Oncol. 2013;20:753-8.
42. Iacobone M, Citton M, Viel G, Boetto R, Bonadio I, Tropea S, et al. Unilateral adrenal hyperplasia: a novel cause of surgically correctable primary hyperaldosteronism. Surgery. 2012;152:1248-55.
43. Harvey A, Pasieka JL, Kline G, So B. Modification of the protocol for selective adrenal venous sampling results in both a significant increase in the accuracy and necessity of the procedure in the management of patients with primary hyperaldosteronism. Surgery. 2012;152:643-9. discussion 9-51.
44. .•• Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, et al. Adrenal venous sampling: evaluation of the German Conn's registry. Hypertension. 2011;57:990-5. This study demonstraterd the importance of high throughput in enhancing cannulation success rate and reported markedly improved success rates among German centers performing AVS after the introduction of a variety of reforms including the creation of standard AVS operating procedures, restricting the procedure to 1-2 proceduralists at each center, use of CTscanning to locate the adrenal veins prior to AVS and point-of-care cortisol testing.
45. Betz MJ, Degenhart C, Fischer E, Pallauf A, Brand V, Linsenmaier U, et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol. 2011;165:301-6.
46. Rossi E, Regolisti G, Perazzoli F, Negro A, Grasselli C, Santi R, et al. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism. Am J Hypertens. 2011;24:1280-5.
47. Viste K, Grytaas MA, Jorstad MD, Jossang DE, Hoyden EN, Fotland SS, et al. Efficacy of adrenal venous sampling is increased by point of care cortisol analysis. Endocr Connect. 2013;2:236-42.
48. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25 Suppl 1:S143-58. (Pubitemid 41686069)
49. Onozawa S, Murata S, Tajima H, Yamaguchi H, Mine T, Ishizaki A, et al. Evaluation of right adrenal vein cannulation by computed tomography angiography in 140 consecutive patients undergoing adrenal venous sampling. Eur J Endocrinol. 2014;170:601-8.
50. Park SI, Rhee Y, Lim JS, Park S, Kang SW, Lee MS, et al. Right adrenal venography findings correlated with C-arm CT for selection during C-arm CT-assisted adrenal vein sampling in primary aldosteronism. Cardiovasc Intervent Radiol. 2013.
51. Kline GA, Pasieka JL, Harvey A, So B, Dias VC. A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism. J Hum Hyperten. 2013.
52. Monticone S, Satoh F, Giacchetti G, Viola A, Morimoto R, Kudo M, et al. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension. 2012;59:840-6.
53. Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, et al. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Invest. 2013;36:564-7.
54. Lau JH, Sze WC, Reznek RH, Matson M, Sahdev A, Carpenter R, et al. A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clin Endocrinol (Oxf). 2012;76:182-8.
55. Dekkers T, Deinum J, Schultzekool LJ, Blondin D, Vonend O, Hermus AR, et al. Plasma metanephrine for assessing the selectivity of adrenal venous sampling. Hypertension. 2013;62:1152-7.
56. Baba Y, Hayashi S, Nakajo M. Are catecholamine-derived indexes in adrenal venous sampling useful for judging selectivity and laterality in patients with primary aldosteronism? Endocrine. 2013;43:611-7.
57. Kupers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97:3530-7.
58. Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab. 2014:jc20133789.
59. Candy SWC, Soh LM, Lau JH, Reznek R, Sahdev A, Matson M, et al. Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf). 2013.
60. Lu CC, Wu VC, Wu KD, Liu KL, Lin WC, Cheng MF, et al. Prognostic value of semiquantification NP-59 SPECT/CT in primary aldosteronism patients after adrenalectomy. Eur J Nucl Med Mol Imaging. 2014.
61. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012;97:100-9.
62. Rutherford JC, Taylor WL, Stowasser M, Gordon RD. Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg. 1998;22:1243-5. (Pubitemid 28514344)
63. Doi M, Satoh F, Maekawa T, Nakamura Y, Fustin JM, Tainaka M, et al. Isoform-specific monoclonal antibodies against 3beta-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. J Clin Endocrinol Metab. 2014;99:E257-62.
64. Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567-74.
65. Volpe C, Hoog A, Ogishima T, Mukai K, Lu M, Thoren M, et al. Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. J Clin Pathol. 2013;66:351-4.
66. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:863-9. (Pubitemid 38680454)
67. Kaplan NM. Primary aldosteronism: evidence against a second epidemic. J Hypertens. 2012;30:1899-902.
68. Funder JW. Primary aldosteronism: are we missing the wood for the trees? Horm Metab Res. 2012;44:251-3.
69. Funder JW. Ultimately we are in furious agreement. J Hypertens. 2012;30:1903-5.
70. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-50. (Pubitemid 38368386)
71. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg. 1996;131:646-50. (Pubitemid 26175585)
72. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-8. (Pubitemid 350287534)
73. Strauch B, Petrak O, Zelinka T, Wichterle D, Holaj R, Kasalicky M, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens. 2008;21:1086-92.
74. .•• Bernini G, Bacca A, Carli V, Carrara D, Materazzi G, Berti P, et al. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Invest. 2012;35:274-80. In this study involving 60 patients with PA (19 with APA and 41 with BAH), surgery in APAwas more effective in reducing blood pressure and in reducing left ventricular massthan the use of specific medication aimed at blocking aldsoterone action in BAH, thus supporting the need to clinically differentiate these two PA subtypes.
75. .• Miyake Y, Tanaka K, Nishikawa T, Naruse M, Takayanagi R, Sasano H, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61:35-40. Analysis of data from 1706 patients with PA revealed that, (1) among those with APA, surgical, but not medical, treatment was significantly associated with amelioration of hypertension whereas (2) among patients with hyperplastic forms of PA (mostly BAH), there was no relationship between either surgical or medical treatment and the prognosis of hypertension. These findings again support subtype testing in order to identify those individuals with unilateral PAwho will benefit from surgery.
76. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60:618-24.
77. Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem. 2009;55:1155-62.
78. Hinchliffe E, Carter S, Owen LJ, Keevil BG. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B. 2013;913-914:19-23.
79. Van DGJG, Dubland J, Liu HF, Wang A, Joseph C, Holmes DT. Determination of serum aldosterone by liquid chromatography and tandem mass spectrometry: a liquid-liquid extraction method for the ABSCIEX API-5000 mass spectrometry system. J Clin Pathol. 2012;65:457-62.
80. Camenzind AG, van der Gugten JG, Popp R, Holmes DT, Borchers CH. Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension. Clin Proteomics. 2013;10:20.
81. Carter S, Owen LJ, Kerstens MN, Dullaart RP, Keevil BG. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem. 2012;49:570-9. The paper reported a mass spectrometric method for measuing PRA which has the potential to greatly increase reliability and reproducibility when screening for PA by ARR testing.
82. Shimabuku M, Sasaki A, Higa M, Kakazu M, Asato M, Shiroma H. Single-incision laparoscopic adrenalectomy for primary aldosteronism: report of a case. Surg Today. 2011;41:1306-9.
83. Colon MJ, Lemasters P, Newell P, Divino C,Weber KJ, Chin EH. Laparoscopic single site adrenalectomy using a conventional laparoscope and instrumentation. J Soc Laparoendosc Surg. 2011;15:236-8.
84. Parthasarathy HK, Menard J, White WB, Young Jr WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-90.
85. Amar L, Azizi M, Menard J, Peyrard S, Plouin PF. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens. 2013;31:624-9. discussion 9.
86. Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385-403.
87. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, et al. A new mode ofmineralocorticoid receptor antagonismby a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-40.
88. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453-63.
89. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab. 2011;96:2813-20.
90. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, et al. Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. J Hum Hypertens. 2011;25:592-9.
91. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013;143:978-83.
92. .•• Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-72. This landmark paper reported a germline mutation in KCNJ5, a potassium channel gene, in a family with florid PA, and somatic KCNJ5 mutations in 8 (36%) of 22 APAs. When expressed in vitro, the mutations led to increased sodium conductance and cell depolarization, which in adrenal glomerulosa cells produces calcium entry, the signal for aldosterone production and cell proliferation.
93. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97:E1532-9.
94. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, et al. A Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98:E1861-5.
95. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235-40.
96. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59:587-91.
97. Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, Buffolo F, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 Mutations in Aldosterone-Producing Adenomas. Hypertension. 2014;63:188-95.
98. Akerstrom T, Crona J, Delgado VA, Starker LF, Cupisti K, Willenberg HS, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE. 2012;7:e41926.
99. Scholl UI, Nelson-Williams C, Yue P, Grekin R,Wyatt RJ, Dillon MJ, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. PNAS. 2012;109:2533-8.
100. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59:592-8.
101. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab. 2012;97:1311-9.
102. 2+ ATPase calcium channel) in much smaller proportions (5% and 2% respectively) of APAs.
103. .• Scholl UI, Goh G, Stolting G, de Oliviera RC, Choi M, Overton JD, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050-4. This paper reported somatic mutations in CACNA1D (encodes a voltage-gated calcium channel) in 11% of APAs.
104. Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055-60.
105. Murthy M, Xu S, Massimo G,Wolley M, Gordon RD, Stowasser M, et al. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension. 2014;63:783-9.